Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A phase II, open-label, safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors

Kulke M, Bergsland E, Ryan DP, Clark JW, Enzinger PC, Michelini A, Kinsella K, Fogler W, Venook A, Fuchs C. . A phase II, open-label, safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Proc Annu Meet Am Soc Clin Oncol. 2003; 22:A958.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.